Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-867: SBRT With or Without Pembrolizumab in Medically Inoperable Stage I–IIA NSCLC
2018-004320-11Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing SBRT + Pembrolizumab with SBRT + Placebo (2 arms). Primary endpoints: Event-Free Survival (EFS) and Time to Death or Distant Metastases (TDDM). Started Apr 2019; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-004320-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004320-11.